AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Acute Lymphocytic Leukemia Refractory

CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: CD180 CART CAV Regimen for R/R Ph- B-ALL NCT05657652NA1 site๐Ÿ“ Suzhou The First Affiliated Hospital of Soochow University ยท Tests: cladribine, cytarabine,venetoclax Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT07572136Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: TSLPR-CART, Cyclophosphamide, Fludarabine KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia NCT07246707Phase 11 site๐Ÿ“ Hangzhou Zhejiang University ยท Tests: KSV01 Injection CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site๐Ÿ“ Prague Institute of Hematology and Blood Transfusion, Czech Republโ€ฆ ยท Tests: Autologous CAR19 T lymphocytes VHAG in Treating R/R T-ALL/LBL NCT06742463Phase 21 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: Venetoclax, homoharringtonine, Cytarabine (Ara-C), G-CSF Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946Phase 1, Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: CD5-targeted CAR-T cells Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia NCT07328503Phase 21 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies NCT06316427Phase 1, Phase 24 sites๐Ÿ“ Beijing๐Ÿ“ Shanghai๐Ÿ“ Shanghai Beijing GoBroad Hospital ยท Tests: Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia NCT07361029Phase 11 site๐Ÿ“ Riyadh King Faisal Specialist Hospital & Research Center ยท Tests: CAR T cells chimeric antigen receptor cells Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia NCT03263572Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Blinatumomab, Cytarabine, Methotrexate, Ponatinib Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies NCT05887167Phase 11 site๐Ÿ“ Los Angeles Joshua Sasine, MD, PhD ยท Tests: autologous hematopoietic stem cells added to planned CAR T Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia NCT05366218Phase 1, Phase 211 sites๐Ÿ“ Freiburg im Breisgau๐Ÿ“ Tรผbingen๐Ÿ“ Ulm University Hospital Tuebingen ยท Tests: Tafasitamab Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies NCT06037018Phase 11 site๐Ÿ“ Tianjin CytoCares Inc ยท Tests: CC312 Venetoclax Basket Trial for High Risk Hematologic Malignancies NCT05292664Phase 15 sites๐Ÿ“ San Francisco๐Ÿ“ Aurora๐Ÿ“ Atlanta Andrew E. Place, MD ยท Tests: Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) NCT06207123Phase 1, Phase 22 sites๐Ÿ“ Chicago๐Ÿ“ Rochester University of Chicago ยท Tests: LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate CD-19 CAR-T Cell for Pediatric ALL or Lymphoma NCT06866873NA1 site๐Ÿ“ Hong Kong Hong Kong Children's Hospital ยท Tests: CAR-T MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia NCT07371403NA1 site๐Ÿ“ Amman King Hussein Cancer Center ยท Tests: MB-CART19.1 Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia NCT07133997Phase 11 site๐Ÿ“ Duarte City of Hope Medical Center ยท Tests: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies NCT06227026Phase 11 site๐Ÿ“ Salt Lake City University of Utah ยท Tests: Anti-CD19 CAR-T cells Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ฮถ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) NCT03938987Phase 1, Phase 26 sites๐Ÿ“ Calgary๐Ÿ“ Calgary๐Ÿ“ Calgary University of Alberta ยท Tests: autologous CD19-directed chimeric antigen receptor (CAR) T-cells Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL NCT07244406Phase 21 site๐Ÿ“ Beijing Hebei Senlang Biotechnology Inc., Ltd. ยท Tests: S1904 CD19 CAR-T Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab NCT06287229Phase 1, Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD, Mini-hyper-CVD Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies NCT07312630EARLY Phase 11 site๐Ÿ“ Hefei PersonGen BioTherapeutics (Suzhou) Co., Ltd. ยท Tests: LV009 Injection Infusion Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors NCT03934372Phase 1, Phase 223 sites๐Ÿ“ Ghent๐Ÿ“ Paris๐Ÿ“ Paris Incyte Biosciences International Sร rl ยท Tests: Ponatinib Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation NCT07297576NA1 site๐Ÿ“ Tianjing Institute of Hematology & Blood Diseases Hospital, China ยท Tests: Sulforaphane HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant NCT03326921Phase 11 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL NCT05495035Phase 14 sites๐Ÿ“ Hefei๐Ÿ“ Jinan๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: Olverembatinib, APG-2575, Dexamethasone
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy